Study Population
In GACRS, 1151 subjects with asthma had plasma samples available for metabolomic profiling, and in CAMP, 911 subjects with asthma had suitable plasma samples extracted at the end of trial (Table 1). In the original CAMP trial, no significant difference in lung function outcomes between the study arms was found 21.
Table 1
Characteristics of the Discovery and Validation Populations
|
DICOVERY GACRS
(n = 1151)
|
VALIDATION CAMP
(n = 911)
|
Age [yrs]; Mean (SD)
|
9.22 (1.88)
|
12.94 (2.14)
|
Sex; Male (%)
|
682 (59.3%)
|
549 (60.3%)
|
Female (%)
|
469 (40.7%)
|
362 (39.7%)
|
Height [cm]; Mean (SD)
|
132.66 (11.85)
|
155.89 (13.35)
|
Weight [kg]; Mean (SD)
|
33.02 (11.49)
|
53.23 (17.32)
|
BMI [kg/m2]; Mean (SD)
|
18.28 (3.77)
|
21.42 (4.70)
|
Race; White (%)
|
-
|
630 (69.2%)
|
Black (%)
|
-
|
117 (12.8%)
|
Hispanic (%)a
|
1151 (100%)
|
84 (9.2%)
|
Other (%)
|
-
|
80 (8.8%)
|
Treatment Armb; Budesonide n (%)
|
-
|
270 (29.6%)
|
Nedocromil n (%)
|
-
|
269 (29.5%)
|
Placebo n (%)
|
-
|
372 (40.8%)
|
a GACRS represents a unique population isolate where participants were selected on the basis of having 6 or more great-grandparents born within the central valley of Costa Rica |
b The CAMP population were from a completed clinical trial |
GACRS Metabo-Endotypes
A total of 2, 2, 2, and 3 clusters of GACRS asthmatics were identified based on metabolite residuals from the C8-pos, C18-neg, HILIC-pos and Amide-neg platforms respectively. We applied SNF to fuse the networks from the four platforms, with convergence after 10 iterations, and spectral clustering resulting in five clusters designated as the asthma metabo-endotypes containing 213, 270, 222, 232, and 214, asthma cases respectively (eFigure2). Based on the Adjusted Rand Index (ARI), the fused network clusters were most similar to those of the Amide-neg platform (ARI = 0.297) (eTable3).
There was no difference between the clusters in terms of sex, age, BMI, vitamin D level, or current smoking status (p > 0.5) (Table 2). However, there was a significant difference across the endotypes in measures of lung function: pre-bronchodilator FEV1/FVC ratio (p = 8.25x10− 5) for which endotype2 had the lowest ratio (mean = 83.1%, range = 50.6%-98.8%) and endotype3 the highest (mean = 86.5%, range = 64.2%-99.9%) and post-bronchodilator FEV1/FVC ratio (p = 1.82x10− 5). Again, endotype2 (mean = 85.9%, range = 52.2%-100%) was the lowest and endotype3 (mean = 89.1%, range = 69.0%-100%) the highest. The same pattern was observed when considering percent predicted FEV1/FVC ratio (pre-bronchodilator p = 4.46x10− 5, post-bronchodilator p = 1.00x10− 5) (Fig. 1). There was also a significant difference in percent predicted FVC across the endotypes (eFigure3). The endotypes differed in the use of oral (p = 0.007) and inhaled (p = 4.97x10− 13) corticosteroids and the use of beta2-agonists (p = 3.25x10− 10). Asthma cases in endotype2 were the most likely to have taken oral steroids (57.8%) or beta2-agonists (30.4%) in the previous year, but the least likely to have taken inhaled steroids (33.7%). Endotype3 had the lowest number who reported use the use of beta2-agonists in the previous year (eFigure4). Consequently, endotype2 was designated the “most-severe” asthma endotype, and endotype3 the “least-severe”.
Table 2
Differences in characteristics between the five GACRS asthma metabo-endotypes
GACRS Variable
|
Endotype1
|
Endotype2
|
Endotype3
|
Endotype4
|
Endotype5
|
p-value
|
n = 213
|
n = 270
|
n = 222
|
n = 232
|
n = 214
|
Demographic Characteristics
|
Sex [Male, n (%)]
|
125
|
(58.7%)
|
160
|
(59.3%)
|
136
|
(61.3%)
|
133
|
(57.3%)
|
128
|
(59.8%)
|
0.941
|
|
Age [mean (SD)]
|
9.21
|
(1.82)
|
9.23
|
(1.83)
|
9.27
|
(1.84)
|
9.14
|
(2.02)
|
9.28
|
(1.87)
|
0.932
|
|
BMI [mean (SD)]
|
18.3
|
(3.84)
|
18.4
|
(3.66)
|
18.4
|
(3.83)
|
18.3
|
(3.81)
|
17.9
|
(3.73)
|
0.577
|
|
Serum Vitamin D (ng/ml) [mean (%)]
|
37.4
|
(11.6)
|
37.6
|
(10.8)
|
35.2
|
(9.0)
|
37.5
|
(12.6)
|
38.0
|
(14.3)
|
0.870
|
|
Current smoking exposure [Yes, n (%)]
|
53
|
(24.9%)
|
68
|
(25.2%)
|
53
|
(23.9%)
|
58
|
(25.0%)
|
52
|
(24.3%)
|
0.995
|
Lung Function
|
Pre-bronchodilator FEV1 [mean (SD)]
|
1.76
|
(0.48)
|
1.78
|
(0.46)
|
1.78
|
(0.48)
|
1.79
|
(0.56)
|
1.77
|
(0.53)
|
0.980
|
|
Pre-bronchodilator FVC [mean (SD)]
|
2.09
|
(0.57)
|
2.16
|
(0.56)
|
2.08
|
(0.58)
|
2.13
|
(0.64)
|
2.11
|
(0.63)
|
0.588
|
|
Pre-bronchodilator FEV1 / FVC [mean (SD)]
|
84.34
|
(8.60)
|
83.14
|
(6.64)
|
86.16
|
(7.03)
|
83.81
|
(8.52)
|
84.43
|
(8.36)
|
8.25E-05*
|
|
Post-bronchodilator FEV1 [mean (SD)]
|
1.85
|
(0.52)
|
1.87
|
(0.48)
|
1.86
|
(0.48)
|
1.88
|
(0.57)
|
1.85
|
(0.53)
|
0.942
|
|
Post-bronchodilator FVC [mean (SD)]
|
2.13
|
(0.59)
|
2.19
|
(0.56)
|
2.1
|
(0.56)
|
2.17
|
(0.64)
|
2.14
|
(0.63)
|
0.595
|
|
Post-bronchodilator FEV1 / FVC ([mean (SD)]
|
87.10
|
(7.55)
|
85.87
|
(6.06)
|
89.10
|
(5.82)
|
87.15
|
(7.22)
|
86.97
|
(7.45)
|
1.82E-05*
|
|
% predicted Pre-bronchodilator FEV1 [mean (SD)]
|
97.40
|
(16.60)
|
100.00
|
(16.40)
|
98.40
|
(16.90)
|
99.00
|
(18.30)
|
99.00
|
(17.60)
|
0.453
|
|
% predicted Pre-bronchodilator FVC [mean (SD)]
|
103.00
|
(16.40)
|
108.00
|
(15.50)
|
101.00
|
(16.20)
|
105.00
|
(16.20)
|
105.00
|
(17.80)
|
2.11E-4*
|
|
% predicted Pre-bronchodilator FEV1 / FVC [mean (SD)]
|
94.80
|
(9.55)
|
93.00
|
(7.50)
|
96.90
|
(7.78)
|
94.20
|
(9.52)
|
95.00
|
(9.22)
|
4.46E-05*
|
|
% predicted Post-bronchodilator FEV1 [mean (SD)]
|
102.00
|
(16.10)
|
105.00
|
(15.20)
|
103.00
|
(16.20)
|
104.00
|
(16.80)
|
103.00
|
(16.20)
|
0.192
|
|
% predicted Post-bronchodilator FVC [mean (SD)]
|
104.00
|
(15.80)
|
109.00
|
(15.10)
|
103.00
|
(15.60)
|
106.00
|
(16.00)
|
106.00
|
(17.20)
|
9.95E-05*
|
|
% predicted Post-bronchodilator FEV1 / FVC [mean (SD)]
|
98.00
|
(8.46)
|
96.60
|
(6.81)
|
100.00
|
(6.37)
|
97.90
|
(8.04)
|
97.80
|
(8.24)
|
1.00E-05*
|
Indices of Asthma Severity
|
Use of oral steroids in previous year [Yes, n (%)]
|
96
|
(45.1%)
|
156
|
(57.8%)
|
118
|
(53.2%)
|
126
|
(54.3%)
|
93
|
(43.5%)
|
0.007*
|
|
Use of inhaled steroids in previous year [Yes, n (%)]
|
138
|
(64.8%)
|
91
|
(33.7%)
|
139
|
(62.6%)
|
123
|
(53.0%)
|
97
|
(45.3%)
|
4.97E-13*
|
|
Use of short acting beta2-agonists in previous year [Yes, n (%)]
|
25
|
(11.7%)
|
82
|
(30.4%)
|
17
|
(7.7%)
|
45
|
(19.4%)
|
47
|
(22.0%)
|
3.25E-10*
|
|
Any asthma medication in previous year [Yes, n (%)]
|
209
|
(98.1%)
|
256
|
(94.8%)
|
217
|
(97.7%)
|
229
|
(98.7%)
|
204
|
(95.3%)
|
0.046*
|
|
Ever Hospitalized for asthma [Yes, n (%)]
|
80
|
(37.6%)
|
117
|
(43.3%)
|
95
|
(42.8%)
|
106
|
(45.7%)
|
90
|
(42.1%)
|
0.522
|
|
Ever visited ER for asthma [Yes, n (%)]
|
208
|
(97.7%)
|
259
|
(95.9%)
|
214
|
(96.4%)
|
224
|
(96.6%)
|
206
|
(96.3%)
|
0.886
|
Allergic Phenotypes
|
Log10 blood eosinophils [mean (SD)]
|
2.56
|
(0.41)
|
2.67
|
(0.35)
|
2.55
|
(0.46)
|
2.58
|
(0.41)
|
2.60
|
(0.43)
|
0.009*
|
|
Eosinophilic asthma (count > 300) [Yes, n (%)]
|
127
|
(59.6%)
|
202
|
(74.8%)
|
142
|
(64.0%)
|
136
|
(58.6%)
|
143
|
(66.8%)
|
0.006
|
|
Log10 IgE [mean (SD)]
|
2.52
|
(0.70)
|
2.48
|
(0.69)
|
2.52
|
(0.65)
|
2.45
|
(0.69)
|
2.57
|
(0.61)
|
0.344
|
|
Number of positive skin prick tests [mean (SD)]
|
3.12
|
(1.77)
|
3.02
|
(1.91)
|
2.94
|
(1.89)
|
3.14
|
(1.83)
|
3.02
|
(1.77)
|
0.784
|
|
Prevalent Hay Fever [Yes, n (%)]
|
79
|
(37.1%)
|
74
|
(27.4%)
|
80
|
(36.0%)
|
66
|
(28.4%)
|
67
|
(31.3%)
|
0.076
|
|
Prevalent Atopic Dermatitis [Yes, n (%)]
|
10
|
(4.7%)
|
12
|
(4.4%)
|
7
|
(3.2%)
|
8
|
(3.4%)
|
17
|
(7.9%)
|
0.142
|
Mean and standard errors for the specified metric in each endotype are shown
There was also evidence of a significant difference in allergic phenotypes across the endotypes. Endotype2 has the highest levels of blood eosinophils (log10 eosinophil count = 2.67, range: 1.0 to 3.41) and the highest percentage of individuals with eosinophilic asthma (74.8%) defined as > 300 cells/µL 22 (eFigure5).
Validating Metabo-endotypes in CAMP
The recapitulated endotypes contained 99, 375, 45, 207 and 185 CAMP asthma cases. The significant difference across endotypes for FEV1/FVC ratio pre- and post- bronchodilator validated in CAMP with an almost identical pattern (Table 3 and Fig. 1). Given that prior to sample collection CAMP subjects had been randomized to differing treatment regimens, we could not directly compare medication use and no significant differences were observed (eFigure6).
Table 3
Differences in characteristics between the five CAMP asthma metabo-endotypes
CAMP Variable
|
Endotype1
|
Endotype2
|
Endotype3
|
Endotype4
|
Endotype5
|
p-value
|
n = 99
|
n = 375
|
n = 45
|
n = 207
|
n = 185
|
Demographic Characteristics
|
Sex [Male, n (%)]
|
58
|
(58.6%)
|
229
|
(61.1%)
|
32
|
(71.1%)
|
125
|
(60.4%)
|
105
|
(56.8%)
|
0.496
|
|
Age [mean (SD)]
|
13.06
|
(2.38)
|
12.91
|
(2.10)
|
12.32
|
(1.61)
|
12.95
|
(2.19)
|
13.08
|
(2.12)
|
0.288
|
|
BMI [mean (SD)]
|
21.18
|
(4.60)
|
21.43
|
(4.66)
|
20.74
|
(4.93)
|
21.31
|
(4.19)
|
21.84
|
(5.31)
|
0.598
|
|
Serum Vitamin D (ng/ml) [mean (%)]
|
33.94
|
(14.61)
|
31.55
|
(14.15)
|
30.49
|
(13.59)
|
28.3
|
(14.31)
|
26.75
|
(11.86)
|
4.83E-05*
|
|
Current smoking exposure [Yes, n (%)]
|
9
|
(9.1%)
|
55
|
(14.7%)
|
6
|
(13.3%)
|
26
|
(12.6%)
|
32
|
(17.3%)
|
0.399
|
|
Race [White, n (%)]
|
72
|
(72.7%)
|
262
|
(69.9%)
|
32
|
(71.1%)
|
140
|
(67.6%)
|
124
|
(67.0%)
|
0.644
|
Lung Phenotypes
|
Pre-bronchodilator FEV1 [mean (SD)]
|
2.55
|
(0.70)
|
2.54
|
(0.74)
|
2.51
|
(0.65)
|
2.62
|
(0.80)
|
2.54
|
(0.71)
|
0.771
|
|
Pre-bronchodilator FVC [mean (SD)]
|
3.29
|
(0.99)
|
3.29
|
(0.94)
|
3.08
|
(0.85)
|
3.36
|
(1.05)
|
3.30
|
(0.91)
|
0.518
|
|
Pre-bronchodilator FEV1 / FVC [mean (SD)]
|
78.31
|
(7.39)
|
77.56
|
(8.89)
|
82.38
|
(8.51)
|
78.47
|
(9.03)
|
77.21
|
(9.46)
|
0.008*
|
|
Post-bronchodilator FEV1 [mean (SD)]
|
2.78
|
(0.78)
|
2.76
|
(0.77)
|
2.68
|
(0.67)
|
2.85
|
(0.85)
|
2.79
|
(0.75)
|
0.614
|
|
Post-bronchodilator FVC [mean (SD)]
|
3.32
|
(1.00)
|
3.34
|
(0.94)
|
3.12
|
(0.83)
|
3.4
|
(1.07)
|
3.36
|
(0.92)
|
0.506
|
|
Post-bronchodilator FEV1 / FVC ([mean (SD)]
|
84.36
|
(6.11)
|
83.07
|
(7.42)
|
86.56
|
(6.83)
|
84.51
|
(7.38)
|
83.42
|
(7.05)
|
0.009*
|
|
% predicted Pre-bronchodilator FEV1 [mean (SD)]
|
94.4
|
(13.6)
|
93.7
|
(14.3)
|
96.0
|
(12.2)
|
94.6
|
(13.4)
|
94.4
|
(14.3)
|
0.831
|
|
% predicted Pre-bronchodilator FVC [mean (SD)]
|
106.0
|
(13.8)
|
105.0
|
(12.5)
|
102.0
|
(11.5)
|
105.0
|
(12.1)
|
107.0
|
(12.1)
|
0.264
|
|
% predicted Pre-bronchodilator FEV1 / FVC [mean (SD)]
|
89.6
|
(8.38)
|
89.1
|
(10.2)
|
94.6
|
(9.34)
|
90.0
|
(10.4)
|
88.8
|
(10.8)
|
0.011*
|
|
% predicted Post-bronchodilator FEV1 [mean (SD)]
|
103.0
|
(12.6)
|
102.0
|
(12.6)
|
102.0
|
(11.2)
|
103.0
|
(11.9)
|
103.0
|
(12.7)
|
0.640
|
|
% predicted Post-bronchodilator FVC [mean (SD)]
|
107.0
|
(14)
|
107.0
|
(12.1)
|
103.0
|
(10.9)
|
107.0
|
(12.2)
|
108.0
|
(12.3)
|
0.210
|
|
% predicted Post-bronchodilator FEV1 / FVC [mean (SD)]
|
96.6
|
(6.79)
|
95.4
|
(8.43)
|
99.4
|
(7.03)
|
96.9
|
(8.59)
|
95.8
|
(8.05)
|
0.016*
|
Indices of Asthma Severity
|
Use of prednisone since last visit [Yes, n (%)]
|
21
|
(21.2%)
|
68
|
(18.1%)
|
8
|
(17.8%)
|
34
|
(16.4%)
|
29
|
(15.7%)
|
0.787
|
|
Use of albuterol since last visit [Yes, n (%)]
|
80
|
(80.8%)
|
313
|
(83.5%)
|
33
|
(73.3%)
|
170
|
(82.1%)
|
151
|
(81.6%)
|
0.530
|
|
Ever hospitalized for asthma [Yes, n (%)]
|
10
|
(10.1%)
|
36
|
(9.6%)
|
2
|
(4.4%)
|
25
|
(12.1%)
|
19
|
(10.3%)
|
0.659
|
|
Ever visited ER for asthma [Yes, n (%)]
|
33
|
(33.3%)
|
129
|
(34.4%)
|
10
|
(22.2%)
|
77
|
(37.2%)
|
54
|
(29.2%)
|
0.238
|
Allergic Phenotypes
|
Log10 blood eosinophils [mean (SD)]
|
2.47
|
(0.40)
|
2.43
|
(0.48)
|
2.45
|
(0.36)
|
2.40
|
(0.48)
|
2.31
|
(0.58)
|
0.050*
|
|
Eosinophilic asthma (count > 300) [Yes, n (%)]
|
54
|
(54.5%)
|
196
|
(52.3%)
|
24
|
(53.3%)
|
104
|
(50.2%)
|
79
|
(42.7%)
|
0.343
|
|
Log10 IgE [mean (SD)]
|
2.77
|
(0.62)
|
2.64
|
(0.62)
|
2.50
|
(0.70)
|
2.64
|
(0.68)
|
2.56
|
(0.69)
|
0.086
|
|
Number of positive skin prick tests [mean (SD)]
|
6.09
|
(3.69)
|
6.14
|
(4.42)
|
4.70
|
(3.53)
|
6.20
|
(4.37)
|
5.99
|
(4.25)
|
0.312
|
|
Prevalent Hay Fever [Yes, n (%)]
|
47
|
(47.5%)
|
165
|
(44.0%)
|
29
|
(64.4%)
|
88
|
(42.5%)
|
93
|
(50.3%)
|
0.061
|
|
Prevalent Atopic Dermatitis [Yes, n (%)]
|
23
|
(23.2%)
|
98
|
(26.1%)
|
15
|
(33.3%)
|
59
|
(28.5%)
|
60
|
(32.4%)
|
0.371
|
The differences in log10 eosinophil count and hay fever prevalence seen in GACRS were borderline significant across the endotypes in CAMP (p = 0.050 and p = 0.061, respectively) although the patterns differed (eFigure5). Additionally, there was evidence that vitamin D levels differed significantly across the endotypes in CAMP (4.83x10− 5).
Key metabolite endotype drivers
In a meta-analysis of GACRS and CAMP, 147, 256, 161, 332 and 269 metabolites were significantly associated with membership of endotypes1, 2, 3, 4, 5 respectively after Bonferroni correction and restriction to those metabolites with concordant directions of effect (eTables4-8, eFigure7). There was some crossover in the metabolites associated with each endotype (eTable9, eFigure8), although the direction of effect often differed. For example, 9,10-diHOME, which has been shown to correlate with lung function23, was at higher levels in the “most-severe”, endotype2 (ß=0.595, p = 1.78x10− 28) relative to all other endotypes, but lower in the “least-severe” endotype3 (ß=-0.4000, p = 2.23x10− 15). Similarly, linoleic acid (ß=0.595, p = 1.78x10− 28) and arachidonic acid (ß=-0.564, p = 1.04x10− 5), which are also thought to play key roles in lung function 23,24, were lower in endotype2 relative to all other endotypes, but higher in the less serve endotype1. We also identified a number of metabolites unique to each endotype (eTable10). However, in general lipid, and in particular phospholipid, levels were among the greatest drivers of membership. Endotype2 was characterized by increased levels of lysophospholipids, phosphatidylcholines (PC), phosphatidylethanolamines (PE), bile acid metabolites, sphingomyelins, triacylglycerols and decreased levels of PUFAs (Fig. 2).
Pathways/classes are named if ≥ 5 metabolites belonging to that class are associated with membership in a given direction (or if they are the most abundant pathway/class for the endotype in a given direction)
Short Chain Carnitines - carbon chain length ≤ 8; Medium Chain Carnitines – carbon chain length 9 to ≤ 16; Long Chain Carnitine – carbon chain length > 16
Genetic drivers of the “most-severe” endotype
Finally, we sought to identify genetic variants that may be associated with membership of the “most-severe” low PUFA, high phospholipid endotype (Endotype2) compared to all other endotypes based on available whole genome sequencing data 14,25. We explored 1,115,764 SNPs after employing a minor allele frequency < 0.05 and r2 > 0.2. Using an additive genetic model adjusting for the first four principal components, age and sex, and meta-analyzing the results across GACRS and CAMP, no SNPs were significant in the meta-analysis at a Bonferroni threshold of 4.48x10− 8. Therefore, we employed a nominal p-value threshold of 0.01 to account for five endotypes and filtered on a concordant direction of effect and a nominal p-value < 0.05 in both cohorts, resulting in 1382 SNPs associated with membership (eFigure9). SNPs were annotated to genes using the biomaRt package 26 and gene set enrichment analysis was conducted using gProfileR 27. This identified an enrichment of “anatomical structure morphogenesis” (p = 1.8x10− 5) and other processes that may be involved in lung development, as well as the microRNA hsa-miR-4517, which has been shown to be altered between asthmatic and normal bronchial epithelial cells 28. Among the top SNPs associated with membership (eTable11) were those mapping to genes associated with pulmonary function and disease including rs7751017 in SMOC2 (p = 6.31x10− 5) and rs11099459 in BMP3, p = 5.23x10− 4); the regulation of pulmonary surfactant homeostasis, rs2120834 in BMPR1B (p = 2.8x10− 4), biosynthesis of glycoproteins including, rs7125946 in GALNT18 (p = 1.01x10− 4), rs1648282 in DUOX1 (p = 2.12x10− 4) and the immune inflammatory response including rs1294053 in SPSB1 (2.57x10− 4) (eTable12).